India Activists Challenge Gilead Patent For Sovaldi Hep C Drug
This article was originally published in PharmAsia News
Gilead's attempt for an India patent for its Sovaldi (sofosbuvir) hepatitis C drug is being challenged by an activist group, the Initiative for Medicines, Access & Knowledge, on grounds the API is a known compound.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.